Search Results for "Where To Buy Pirfenidone"

10:08 EDT 28th May 2015 | BioPortfolio

Matching Channels

None

Matching News

Continue Tx in IPF Even With Decline

(MedPage Today) -- Patients with idiopathic pulmonary fibrosis who have an early decline in FVC while on pirfenidone should stay on treatment.

Boehringer eyes Ofev success in IPF and beyond

Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet that serve to ultimately benefit patients. Boehri...

Boehringer's lung drug to hit EU markets

The prospects for patients in Europe with the rare debilitating and fatal lung disease idiopathic pulmonary fibrosis are looking up with the imminent market arrival of Boehringer Ingelheim's Ofev.Ofev...

Physician Views: Idiopathic pulmonary fibrosis – on the cusp of a revolution; how will forthcoming approvals shape the treatment and development landscapes?

Recently added to the BioPortfolio report store, Physician Views: Idiopathic pulmonary fibrosis – on the cusp of a revolution; how will forthcoming approvals shape the treatment and development lan...

Physician Views: The idiopathic pulmonary fibrosis (IPF) market – let battle commence

Recently added to the BioPortfolio report store, Physician Views: The idiopathic pulmonary fibrosis (IPF) market – let battle commence is a new report from Firstword published on 2015-04-26. This r...

Roche gives timeline for its anti-PD-L1

Roche (SIX:ROG; OTCQX:RHHBY) reported 1Q15 earnings Wednesday and discussed clinical and regulatory plans for its anti-PD-L1 candidate MPDL3280A. The company said it plans to submit a regulatory appli...

ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis

ANDOVER, Mass., March 5, 2015 /PRNewswire/ -- ndd Medical Technologies, a leader in innovative mobile pulmonary function testing (PFT) that employs precise ultrasound technology, announced that i...

InterMune, Inc. - Product Pipeline Review - 2014

Recently added to the BioPortfolio report store, InterMune, Inc. - Product Pipeline Review - 2014 is a new report from Global Markets Direct published on 2014-12-14. This 40-page report is available ...

Matching PubMed Articles

Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein‑47 and collagen type I in rat hepatic stellate cells in vitro.

Pirfenidone (esbiret) is an established anti‑fibrotic and anti‑inflammatory drug used to treat idiopathic pulmonary fibrosis. In the present study, the dose‑dependent effects of pirfenidone on t...

Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC-MS/MS.

A rapid, sensitive and selective ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of pi...

Sensitivity Analyses of the Change in Forced Vital Capacity in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Forced vital capacity (FVC) outcomes in clinical trials in idiopathic pulmonary fibrosis (IPF) can be substantially influenced by the analytic methodology and the handling of missing data. We conducte...

Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary Fibrosis.

Pirfenidone enhances the efficacy of combined radiation and sunitinib therapy.

Radiotherapy is a widely used treatment for many tumors. Combination therapy using anti-angiogenic agents and radiation has shown promise; however, these combined therapies are reported to have many l...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement